Rationale for RAS mutation-tailored therapies.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• RAS mutations are prevalent in various cancers, driving tumor growth.
• Targeting strategies for RAS-dependent tumors are emerging but require refinement.
• Understanding the molecular basis of RAS mutations is key for effective therapies.

Purpose of the Study:

• To review the emerging strategies for targeting RAS-dependent tumors.
• To highlight the importance of patient selection based on specific RAS mutations.
• To discuss the role of understanding mutant RAS protein properties in therapeutic development.

Main Methods:

• Review of clinical and laboratory data on RAS mutations.
• Analysis of biochemical and structural properties of mutant RAS proteins.
• Examination of recent therapeutic approaches, including covalent inhibitors.

Main Results:

• Patient selection based on specific RAS mutations is essential for targeted therapies.
• Knowledge of mutant RAS protein characteristics provides a foundation for drug development.
• Direct inhibition of KRAS G12C demonstrates a successful mutation-tailored strategy.

Conclusions:

• Targeting RAS mutations in cancer is a rapidly evolving field.
• Personalized medicine approaches, guided by specific RAS mutations, are critical.
• The success with KRAS G12C inhibitors sets a precedent for targeting other RAS alterations.